The exciting development of induced pluripotent stem cells (iPSCs), and the discovery that iPSCs can be derived from cord blood (CB), combined with the presence of nonhematopoietic stem and progenitor cells in CB may lead to enhanced therapeutic applicability of this cell source and induce increased CB banking.
